NCT03981627View on ClinicalTrials.gov

A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 6, 2019

Primary Completion Date

June 27, 2020

Study Completion Date

June 27, 2020

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

ADO09 formulation

Subcutaneous injection of ADO09 formulation

DRUG

NovoRapid®

Subcutaneous injection of insulin aspart

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Adocia
All Listed Sponsors
lead

Adocia

INDUSTRY